Prognostic Value of the Number of Circulating Tumor Cells in Patients with Metastatic Non-Small Cell Lung Cancer DOI Creative Commons

Arthur B. Volovetsky,

В. А. Новикова,

Anastasia Boloban

et al.

Micromachines, Journal Year: 2025, Volume and Issue: 16(4), P. 470 - 470

Published: April 15, 2025

Investigating the molecular and genetic characteristics of circulating tumor cells (CTCs) presents a promising approach for personalizing treatment in patients with malignant neoplasms, given limitations traditional biopsy histopathology. This study aimed to isolate, characterize, analyze CTC dynamics peripheral blood 30 metastatic lung cancer develop criteria response prognosis. We detected CTCs before start monitored changes during treatment, correlating these responses evaluated by standard imaging methods. A decrease course therapy was linked favorable response, while stable counts indicated lack poor survival The OS analyzed compared initial number samples. significant reductions median were evident >3 total at baseline those ≤3 (median 26 months, n = 10, vs. 8 19, respectively HR 2.6, 95% CI 1.07 6.4).

Language: Английский

New biomarkers and multiplex tests for diagnosis of aggressive prostate cancer and therapy management DOI Creative Commons
Milan Král, Daniela Kurfürstová,

Pavel Zemla

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: Feb. 25, 2025

Despite improving diagnostic possibilities, the incidence of prostate cancer is increasing, but we are not able to reduce mortality rate. While PSA, 4K score, PCA3 and other urinary markers, ExoDX, SelectMDX, Confirm MDx or MiPS tests used identify potential carriers, Decipher, Prolaris Oncotype DX assess aggressiveness proven in order stratify patients for early delayed treatment. More modern forms treatment advanced disease include second-generation antiandrogens PARP inhibitors. By assessing genetic mutations (e.g. BRCA1, BRCA2 genes, single nucleotide polymorphism) presence splice variants androgen receptor (ARV7), whom planned may be expected ineffective thus choose modalities. In present review article, offer a comprehensive overview current that find application diagnosis cancer.

Language: Английский

Citations

0
The Prognostic Role of miR-375 in Head and Neck Squamous Cell Carcinoma: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis DOI Open Access
Mario Dioguardi, Gennaro Musella, Maria Eleonora Bizzoca

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(5), P. 2183 - 2183

Published: Feb. 28, 2025

Head and Neck Squamous Cell Carcinoma (HNSCC) is a heterogeneous group of malignancies with poor survival outcomes, particularly in advanced stages. Identifying prognostic biomarkers could help improve patient management. miR-375, small non-coding RNA, has been shown to influence tumor growth immune responses, making it candidate biomarker. This study aims evaluate the role miR-375 expression predicting outcomes HNSCC patients. A systematic review meta-analysis were conducted according PRISMA guidelines, incorporating data from six studies TGCA cohort, encompassing 452 Fixed-effects models applied calculate aggregated hazard ratios (HRs) for overall (OS). Kaplan-Meier curves analyzed using Tierney method, Trial Sequential Analysis (TSA) was performed assess statistical power. Low associated poorer OS, an HR 1.23 (95% CI: 1.10-1.37). Subgroup analysis showed consistent trends across oral laryngeal squamous cell carcinoma. Sensitivity confirmed these findings. TSA revealed that although number patients sufficient, power insufficient confirm predefined risk reduction ratio (RRR) 49%. Data cohort supported findings, OS 1.32 0.96-1.8). worse patients, indicating its potential as biomarker therapeutic target. However, retrospective nature included underscores need prospective research validate

Language: Английский

Citations

0
Platelets, chromogranin A and C-reactive protein predict therapy failure of metastatic hormone-sensitive prostate cancer while miR-375 outperforms PSA in stratifying castration-resistant prostate cancer DOI
Eva Szczyrbová,

Radka Spurná,

Kateřina Holá

et al.

Journal of Molecular Diagnostics, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
Prognostic Value of the Number of Circulating Tumor Cells in Patients with Metastatic Non-Small Cell Lung Cancer DOI Creative Commons

Arthur B. Volovetsky,

В. А. Новикова,

Anastasia Boloban

et al.

Micromachines, Journal Year: 2025, Volume and Issue: 16(4), P. 470 - 470

Published: April 15, 2025

Investigating the molecular and genetic characteristics of circulating tumor cells (CTCs) presents a promising approach for personalizing treatment in patients with malignant neoplasms, given limitations traditional biopsy histopathology. This study aimed to isolate, characterize, analyze CTC dynamics peripheral blood 30 metastatic lung cancer develop criteria response prognosis. We detected CTCs before start monitored changes during treatment, correlating these responses evaluated by standard imaging methods. A decrease course therapy was linked favorable response, while stable counts indicated lack poor survival The OS analyzed compared initial number samples. significant reductions median were evident >3 total at baseline those ≤3 (median 26 months, n = 10, vs. 8 19, respectively HR 2.6, 95% CI 1.07 6.4).

Language: Английский

Citations

0